HCP Live

HCPLive® is a detailed online platform that offers the latest clinical news and information tailored for healthcare professionals. It aims to equip physicians with valuable specialty and disease-specific resources to enhance patient care. At HCPLive®, users can access breaking news, insightful video interviews with medical experts, extensive coverage of medical conferences, updates on finance and practice management, as well as thoughtful commentary and analysis from physician writers, among other resources. Physicians Money Digest (PMD) serves as a reliable online financial guide for doctors, addressing various topics such as personal finance, investment strategies, retirement planning, practice management, and lifestyle choices. PMD features daily updates, expert advice, and articles penned by both current and former doctors, financial professionals, and healthcare journalists.

National, Trade/B2B

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

#331001

United States

#117492

Health/Medicine

#993

Traffic sources

Monthly visitors

Articles

Reaching for Minimal Symptom Expression in gMG With Inebilizumab, with Richard Nowak, MD, MS

1 day ago | hcplive.com | Victoria Johnson

New data from the phase 3 MINT trial (NCT04524273) has continued to support inebilizumab’s effect of reducing exacerbations and rescue therapy use in people with generalized myasthenia gravis (MG), while successfully tapering steroids.1 These findings were presented at the Myasthenia Gravis Foundation of America (MGFA) 2025 meeting in The Hague last month by principal investigator Richard Nowak, MD, MS, associate professor of neurology, and director of Clinical & Translational Neuromuscular...
Efzofitimod Shows Promising Early Efficacy in Systemic Sclerosis-Related Interstitial Lung Disease

1 day ago | hcplive.com | Victoria Johnson

Efzofitimod has demonstrated early signs of clinical efficacy in people with diffuse and limited systemic sclerosis-related interstitial lung disease (SSc-ILD).1“We are excited to see early signals emerging across multiple skin assessment measures from this initial interim analysis, and we are particularly encouraged by the stable or improved modified Rodnan Skin Score (mRSS), a measure of skin fibrosis, seen in all patients,” Sanjay S.
Rheumatology Month in Review: May 2025

2 days ago | hcplive.com | Victoria Johnson

In May, the rheumatology landscape was marked by key clinical trial readouts, expanded efficacy data for approved therapies, and new insights into disease burden and management strategies. Notably, Merck KGaA reported positive phase 2 results for enpatoran in patients with cutaneous and systemic lupus erythematosus, with the agent showing promising skin-specific efficacy and a favorable safety profile.
Research Finds Variable Biologic Use for Autoimmune Diseases During and After Pregnancy

2 days ago | hcplive.com | Victoria Johnson

A new cohort study found that biologic use declined in patients with autoimmune diseases during pregnancy and only partially rebounded after. The study found high levels of variation in biologic use, highlighting a need for indication-specific risk-benefit assessments of biologic use.1According to lead investigator Celeste L. Y.
Diabetes Dialogue: American Diabetes Association Consensus Report on MASLD

3 days ago | hcplive.com | Diana Isaacs |Natalie Bellini

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives! In this episode of Diabetes Dialogue, cohostsDiana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, examine a newly released American Diabetes...
FDA News Recap: May 2025

3 days ago | hcplive.com | Victoria Johnson

Welcome back to our recap of this month's news and updates from the US Food and Drug Administration (FDA)!May 2025 continued a strong year of regulatory momentum, with the FDA advancing a wide range of novel therapies and access-expanding approvals across specialties. From the first TRPM8 agonist eyedrop for dry eye disease to the first biologic for eosinophilic COPD, the month's decisions reflected a growing emphasis on personalized and precision medicine.
ACT-Based Parenting Improves Management of Pediatric Asthma With Comorbid ADHD

4 days ago | hcplive.com | Victoria Johnson

Acceptance and commitment therapy–based parenting program (ACT-PAM) reduced health care use, improved asthma control, and alleviated attention-deficit/hyperactivity disorder (ADHD) symptoms, demonstrating its efficacy in managing pediatric asthma with comorbid ADHD.1“There is a growing call in the literature to move beyond understanding the asthma-ADHD association and toward integrating mental health and medical care.
Methotrexate Not Seen to Have Effect in Knee Osteoarthritis Pain or Effusion-Synovitis

4 days ago | hcplive.com | Victoria Johnson

A new study has found that 1 year of low-dose methotrexate did not reduce pain or effusion-synovitis in patients with knee osteoarthritis (OA) and effusion-synovitis.1“[Previous] findings2 suggest an effect of methotrexate for inflammatory hand OA and a potential effect for knee OA. However, they also highlight the importance of phenotyping participants with knee OA to determine which specific populations, if any, will respond favorably to methotrexate.
Diabetes Dialouge: May 2025 Diabetes Tech & Breakthrough T1D Updates

4 days ago | hcplive.com | Diana Isaacs |Natalie Bellini

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives! In this episode of Diabetes Dialogue, co-hosts hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, discuss significant developments in...
Itepekimab Demonstrates Mixed Phase 3 Results for COPD Exacerbations

1 week ago | hcplive.com | Victoria Johnson

Itepekimab statistically significantly reduced moderate or severe exacerbations in former smokers with (COPD) regardless of eosinophilic phenotype, meeting the primary endpoint of the phase 3 AERIFY-1 trial, but not the primary endpoint of the similar AERIFY-2 trial.1“COPD is a particularly complex disease, and novel approaches are needed to address the multiple underlying biological disease drivers,” George D.